Advertisement
JBC

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Originally published In Press as doi:10.1074/jbc.M202937200 on April 23, 2002

J. Biol. Chem., Vol. 277, Issue 26, 23888-23897, June 28, 2002
This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/26/23888    most recent
M202937200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knuefermann, P.
Right arrow Articles by Sivasubramanian, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knuefermann, P.
Right arrow Articles by Sivasubramanian, N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Myotrophin/V-1, a Protein Up-regulated in the Failing Human Heart and in Postnatal Cerebellum, Converts NFkappa B p50-p65 Heterodimers to p50-p50 and p65-p65 Homodimers*

Pascal KnuefermannDagger, Peter Chen§, Arunima Misra, Shu-Ping Shi, Maha Abdellatif, and Natarajan Sivasubramanian||

From the Winters Center For Heart Failure Research, Molecular Cardiology Unit, Cardiology Section of Department of Medicine, Baylor College of Medicine, Veterans Affairs Medical Center, Houston, Texas 77030

Received for publication, March 26, 2002, and in revised form, April 22, 2002

    ABSTRACT
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Myotrophin/V-1 is a cytosolic protein found at elevated levels in failing human hearts and in postnatal cerebellum. We have previously shown that it disrupts nuclear factor of kappa B (NFkappa B)-DNA complexes in vitro. In this study, we demonstrated that in HeLa cells native myotrophin/V-1 is predominantly present in the cytoplasm and translocates to the nucleus during sustained NFkappa B activation. Three-dimensional alignment studies indicate that myotrophin/V-1 resembles a truncated Ikappa Balpha without the signal response domain (SRD) and PEST domains. Co-immunoprecipitation studies reveal that myotrophin/V-1 interacts with NFkappa B proteins in vitro; however, it remains physically associated only with p65 and c-Rel proteins in vivo during NFkappa B activation. In vitro studies indicate that myotrophin/V-1 can promote the formation of p50-p50 homodimers from monomeric p50 proteins and can convert the preformed p50-p65 heterodimers into p50-p50 and p65-p65 homodimers. Furthermore, adenovirus-mediated overexpression of myotrophin/V-1 resulted in elevated levels of both p50-p50 and p65-p65 homodimers exceeding the levels of p50-p65 heterodimers compared with Adbeta gal-infected cells, where the levels of p50-p65 heterodimers exceeded the levels of p50-p50 and p65-p65 homodimers. Thus, overexpression of myotrophin/V-1 during NFkappa B activation resulted in a qualitative shift by quantitatively reducing the level of transactivating heterodimers while elevating the levels of repressive p50-p50 homodimers. Correspondingly, overexpression of myotrophin/V-1 resulted in significantly reduced kappa B-luciferase reporter activity. Because myotrophin/V-1 is found at elevated levels during NFkappa B activation in postnatal cerebellum and in failing human hearts, this study cumulatively suggests that myotrophin/V-1 is a regulatory protein for modulating the levels of activated NFkappa B dimers during this period.

    INTRODUCTION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Myotrophin/V-1 (Myo/V1)1 protein was initially characterized in the mammalian heart, where it was called myotrophin (1), and in the rat cerebellum, where it was called V-1 (2). It was later found to be ubiquitously expressed in all mammalian tissues (3, 4). Myo/V1 is a 12-kDa ankyrin repeat-containing intracellular protein that has been found at elevated levels in failing human hearts (5) as well as in the hearts of spontaneously hypertensive rats (6). Although Myo/V1 was originally described as a trophic protein (myotrophin) exhibiting growth properties exogenously on rat neonatal myocytes (1), other studies showed that this protein was only present in intracellular space (2, 7-9) and its trophic growth properties on neonatal myocytes were not confirmed (10). Moreover, this protein was originally identified and isolated only from an intracellular location (1), and a transcriptional regulatory function has been proposed (3, 9).

Since its discovery, investigators have proposed various functions for Myo/V1 protein (1-3). In the postnatal rat cerebellum, the cellular level of soluble Myo/V1 was found to be transiently up-regulated immediately after birth and later declined displaying a unique pattern of expression among 120 soluble proteins, implicating its role during postnatal cerebellum development (2). Because of its aberrant expression in genetically defective cerebellar granular cells, this protein was proposed to play a role in granular cell differentiation process (Unigene Mm.4123) (7). To date, however, the molecular function of Myo/V1 protein is still lacking. We recently reported that Myo/V1 protein exhibits significant homology to Ikappa Balpha protein and that Myo/V1 can disrupt the NFkappa B-DNA complexes in vitro (3). Utilizing our recombinant Myo/V1 protein, the NMR structure of Myo/V1 was determined (11, 12), and the ankyrin repeats of Myo/V1 exhibited structural features similar to those of Ikappa Balpha (13, 14) at the three-dimensional level.

In response to a variety of pathophysiological and developmental signals, the NFkappa B/Rel family of transcription factors are activated and form different types of hetero- and homodimers among themselves to regulate the expression of target genes containing kappa B-specific binding sites (15, 16). Among the activated NFkappa B dimers, the p50-p65 heterodimers are known to be involved in enhancing the transcription of target genes and the p50-p50 homodimers in transcriptional repression (17-22). However, the p65-p65 homodimers are known for both transcriptional activation and repressive activity against target genes (23-31). NFkappa B activation is regulated at multiple levels. The dynamic shuttling of the inactive NFkappa B dimers between the cytoplasm and nucleus by Ikappa B proteins (32-35) and its termination by phosphorylation and proteasomal degradation (36, 37), direct phosphorylation (38), acetylation of NFkappa B factors (39), and dynamic reorganization of NFkappa B subunits among the activated NFkappa B dimers (40-42) have all been identified as key regulatory steps in NFkappa B-mediated transcription process. kappa B DNA binding sites with varied affinities to different NFkappa B dimers (43) have been discovered in the promoters of several eukaryotic genes (16, 20, 22, 44, 45), and the balance between activated NFkappa B homo- and heterodimers ultimately determines the nature and level of gene expression within the cell (18, 22). However, thus far the underlying molecular mechanism for the generation and dynamic reorganization of NFkappa B dimers during chronic activation is unknown. Here, for the first time, we show that Myo/V1 acts as a "zipper chaperone" protein to generate NFkappa B homodimers from monomeric p50 proteins and with its "unzipping" function converts the transcriptionally active p50-p65 heterodimers to transcriptionally repressive homodimers in HeLa cells, thus attenuating NFkappa B-mediated transcription.

    EXPERIMENTAL PROCEDURES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Recombinant Expression Plasmids and Adenoviruses-- Recombinant Myo/V1 protein was expressed in Escherichia coli in two different forms (~12-kDa full-length and histidine-tagged ~14-kDa fusion protein) using pET expression vectors as described before (3). The following mammalian expression plasmids were constructed by recombinant DNA methods. For pcDNA-AM1.1-Myo/V1, because of the poor translation initiation Kozak site in the Myo/V1 mRNA, we engineered a heterologous highly efficient Kozak site into 5'-untranslated region of Myo/V1 so that Myo/V1 is expressed at high levels in mammalian cells. In vitro transcription and translation with pcDNA3-AM1.1-Myo/V1 template DNA confirmed the synthesis of 12-kDa Myo/V1 protein at higher levels than the native Myo/V1 mRNA (data not shown). For pkappa B-tk-luc, the parent chloramphenicol acetyltransferase reporter plasmid containing a minimal thymidine kinase promoter and two kappa B enhancer sites was obtained and replaced with the coding region of luciferase enzyme. pRSV-RelA vector expressing p65 was obtained through the AIDS Research and Reference Reagent Program, Division of AIDS, NIAID, National Institutes of Health. The expression plasmid is from Dr. Gary Nabel and Dr. Neil Perkins. The recombinant adenoviruses expressing Myo/V1 and beta -galactosidase were constructed as follows. For AdMyo/V1/Adbeta gal, the respective expression plasmids pcDNA3-AM1.1-Myo/V1 and pcDNA3-beta gal were incorporated into Ad5 adenovirus through allelic recombination. Recombinant adenoviruses were propagated, purified, and titered as previously reported (46).

Cell Biology Techniques-- HeLa cells (ATCC-CCL2) were maintained in minimal essential medium. Cell fixation and indirect immunofluorescence studies were performed as previously described (47). Cytoplasmic and nuclear extracts were prepared using NE-PERTM nuclear and cytoplasmic extraction reagents (Pierce). Plasmid DNA transient transfection experiments were performed using FuGENE6 reagent (Roche). Luciferase assays were conducted with reagents from Promega Inc. The protein concentration was determined by BCA method using Pierce reagents.

HeLa cells were treated for 2 h with TNF (50 ng/ml) to induce NFkappa B. For superinduction of NFkappa B, cells were further treated with cycloheximide (10 µg/ml). After 2 h of treatment, cells were harvested and subcellular fractionation for cytoplasmic and nuclear extracts were carried out as previously described (48). Briefly, HeLa cells were harvested at 150 × g and Dounce-homogenized in a hypotonic lysis buffer (buffer A; Ref. 49), and nuclei were collected at 4300 × g. The nuclei were extracted with buffer C (49) and were used for GSA and Western blot analysis. After the removal of the nuclei, the supernatant was further centrifuged at 20,000 × g for isolating mitochondrial fractions. The remaining cytosolic supernatant was further concentrated by acetone precipitation. Identical amounts of cytosolic (40 µg), nuclear extract (30 µg), and mitochondrial proteins (35 µg) were fractionated on a 10% Tris-Tricine SDS-PAGE and processed for Myo/V1 ECL immunoblotting.

In Vitro Myo/V1-NFkappa B Interaction Experiments-- Pure recombinant p50 protein was obtained from Promega Inc., and pure truncated recombinant p65Delta (p65 RHRs) protein was obtained from Dr. Gaurishankar Ghosh (50). The p65Delta contains only the Rel DNA binding domain (~31 kDa; aa 19-291) of p65, and the carboxyl terminus containing the transactivating domain of p65 has been removed (50). Monomeric p50 (2.5 ng in 50 µl; 2 nM) and p65Delta (0.5 µg in 50 µl; 7 µM) proteins were separately incubated with increasing concentrations of Myo/V1 (0-100 ng) and the resulting kappa B-DNA complexes from these reactions were analyzed by GSA (3, 46). Because p50 and p65 proteins exhibit high affinity to each other, equimolar concentrations of p50 (16 pmol; 0.8 µg) and p65Delta (16 pmol; 0.5 µg) proteins were mixed and incubated in a binding buffer at 4 °C to preform the p50-p65Delta heterodimers. Later, increasing concentrations of 12-kDa Myo/V1 protein (0-56 pmol; 0-800 ng) were added and incubated for an additional 30 min at 4 °C. Finally, the radiolabeled kappa B oligonucleotides (25,000 cpm) were added and incubated for another 10 min at 4 °C. The resulting kappa B-DNA complexes from these reactions were analyzed by GSA (3, 46). The mobility patterns of the p50-p65Delta , p50-p50, and p65Delta -p65Delta dimers on GSA exactly resemble the previously published patterns for these dimers (43, 51, 52). To identify the nature of Myo/V1-generated NFkappa B dimers, antibodies to p50 (#sc114x; Santa Cruz Biotechnology, Santa Cruz, CA) and p65 (#ab243, Abcam, Cambridge, UK) were added to preformed heterodimers (equimolar mixture of p50 (80 ng) and p65Delta (50 ng) proteins) with increasing concentrations of Myo/V1 (0, 100, 400 ng), and its effects were studied on GSA. This experiment was also repeated with preformed p50-p65Delta heterodimers with 100-fold excess p65Delta protein (5 µg).

Quantification of Individual NFkappa B Dimers in HeLa Cell Nuclear Extracts-- We developed a more accurate method to quantify NFkappa B dimers in mammalian cell nuclear extracts. We chose three kappa B sites from native genes, which have been previously well characterized to exhibit high affinity to individual NFkappa B dimers. The rationale behind this approach is with varied amounts of activated NFkappa B dimers in the mammalian cell, using a single kappa B oligo, which exhibits high affinity to one dimer, and not to others and using it to quantify the various NFkappa B dimers will yield erroneous results. Moreover, the ideal kappa B oligo, which exhibits equal affinity toward all NFkappa B dimers with varied mobilities on GSA to distinguish them, does not exist. Therefore, the conventional kappa B-Igkappa /HIV oligonucleotide (5'-AGTTGAGGGGACTTTCCCAGGC-3' from Santa Cruz Biotechnology, Inc.) was used to quantify only p50-p65 heterodimers because it exhibited high affinity only toward p50-p65 heterodimers. Because this kappa B site exhibited lower affinities toward p50-p50 and p65-p65 homodimers (5- and 15-fold, respectively) (53), we chose two other kappa B oligonucleotides kappa B#SeqB (44) and kappa B#u-iNOS (45), which were previously shown to exhibit high affinity and exclusive specificity toward p50-p50 and p65-p65 homodimers (44, 45). The kappa B#SeqB (5'-GTAGGGGGCCTCCCCGGCTCGAGATCCTATG-3') and kappa B#u-iNOS (5'-GTACCGGAAATTCCGGGCTCGAGATCCTATG-3') oligonucleotides were custom synthesized (Synthetic Genetics, CA) and used for quantifying respective NFkappa B homodimers. To determine the relative levels of various NFkappa B dimers, nuclear extracts (~20 µg) from AdMyo/V1- and Adbeta gal-infected cells were incubated with radiolabeled individual kappa B oligonucleotides (kappa B-Igkappa , #SeqB; #u-iNOS; 25,000 cpm with similar specific activities), and the resulting DNA-protein complexes were fractionated on the same 4% PAGE. Radiographic images of the gels were captured using a STORM 860 imager (Molecular Dynamics, CA) and quantified using ImageQuant 4.2 software. NFkappa B antibody supershifts were done as described previously; however, p65 antibody from Geneka Biotechnology (Montreal, Canada) was used in these experiments. Additionally, heterologous chase experiments were done to further confirm the nature of the NFkappa B dimers.

    RESULTS
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Myo/V1 Is Localized in the Cytoplasm and Nucleus-- Indirect immunofluorescence studies were conducted to locate the native Myo/V1 protein in HeLa cells. Under basal conditions (Fig. 1A), Myo/V1 was predominantly observed in a wide area of the cytoplasm surrounding the nucleus. Further analysis with confocal microscopy revealed that native Myo/V1 was also present in the nucleus to a lesser extent (spotted green fluorescence in Fig. 1C). Upon treatment with TNF for 1 h, Myo/V1 was found to cluster around the perinuclear region in the cytoplasm. Additionally, Myo/V1 was found to increase slightly within the nucleus (green FITC masking the blue DAPI nuclear staining, resulting in pale blue nucleus) suggesting migration of Myo/V1 to the nucleus (Fig. 1B). Because TNF is known to reorganize the cytoskeleton (54-56), the present observation of increased perinuclear clustering and nuclear migration of Myo/V1 in TNF-treated HeLa cells (Fig. 1B) suggests that Myo/V1 might be associated with the cytoskeleton and its associated organelles and might participate in the signal transduction process from these locations.


View larger version (55K):
[in this window]
[in a new window]
  		Fig. 1.   Native Myo/V1 is localized in the cytoplasm and nucleus of HeLa cells. A, detection of Myo/V1 by indirect immunofluorescence light microscopy. HeLa cells under basal conditions were fixed and stained with anti-Myo/V1 antibody and a FITC-conjugated secondary antibody. Nuclei were stained with DAPI, and images of FITC and DAPI staining (60×; A and B) were captured using a phase contrast Nikon Eclipse E800 microscope. A nonfluorescent blue color was assigned for DAPI image during image capture and superimposed with FITC image using Metaview software. B, HeLa cells treated with TNF for 2 h. C, image of untreated HeLa cells was acquired using a laser-scanning microscope. White arrows denote the cytoplasmic and nuclear localization of Myo/V1.

Myo/V1 Translocates to Nucleus during Sustained Induction of NFkappa B-- Cellular partitioning studies were performed to determine the location of Myo/V1 under the NFkappa B inducing conditions. Cells were treated with TNF or TNF plus CHX for 2 h. Cytoplasmic, mitochondrial, and nuclear extracts were prepared and immunoblotted for Myo/V1 protein (Fig. 2). Under basal conditions the majority of Myo/V1 was present in the cytoplasmic fraction (lane 5 in Fig. 2B) and only a small quantity in the nuclear fraction (lane 3 in Fig. 2B). After TNF stimulation for 2 h, Myo/V1 levels in the cytoplasmic fraction did not change significantly (data not shown). However, with TNF plus CHX stimulation, the levels of Myo/V1 reduced significantly in the cytoplasmic fraction compared with control (lanes 5 and 6 in Fig. 2B). Additionally, a simultaneous increase in the levels of Myo/V1 was observed in the nucleus (lane 4 in Fig. 2B), indicating that the translocated Myo/V1 migrated from cytoplasm. We did not observe any Myo/V1 in mitochondrial fractions (lanes 1 and 2 in Fig. 2B). These data suggest that, under acute stress conditions, a major relocalization of Myo/V1 first occurs within the cytoplasm (Fig. 1B), following which Myo/V1 is translocated to the nucleus.


View larger version (63K):
[in this window]
[in a new window]
  		Fig. 2.   Myo/V1 is translocated to nucleus during superinduction of NFkappa B. A, GSA showing the kappa B DNA binding activity of HeLa cell nuclear extracts. Cells were treated for 2 h with TNF (50 ng/ml) (lanes 2 and 3) or TNF plus CHX (10 µg/ml) (lanes 4 and 5) to superinduce NFkappa B. kappa B DNA binding activity was performed with 20 µg of nuclear extracts. B, Western blot analysis of native Myo/V1. HeLa cells were treated with TNF (50 ng/ml) plus CHX (10 µg/ml) for 2 h and cytoplasmic (CYT; 40 µg), mitochondrial (MC; 35 µg), and nuclear (NE; 30 µg) extracts were prepared, fractionated on a 10% Tris-Tricine SDS-PAGE, and processed for ECL immunoblotting. CON, control.

Myo/V1 Physically Interacts with NFkappa B Proteins-- To confirm that Myo/V1 physically interacts with NFkappa B proteins, co-immunoprecipitation studies were conducted both in vitro and in vivo. Fig. 3A shows that, in vitro, p50, p65, and c-Rel proteins strongly interacted with Myo/V1 protein (lanes 2-4). To further confirm these physical interactions in vivo, HeLa cells were treated with diluent (lanes 8-10 in Fig. 3B), TNF plus CHX (lanes 5-7 in Fig. 3B), or phorbol ester (lanes 11-13 in Fig. 3C) for 2 h or infected with AdMyo/V1 for 12 h (lanes 14 and 15 in Fig. 3C), cellular extracts were prepared, and co-immunoprecipitation experiments were conducted. In control diluent-treated cells, Myo/V1 did not associate with any of the NFkappa B proteins (lanes 8-10 in Fig. 3B). However, in TNF plus CHX- or AdMyo/V1-treated cells, Myo/V1 predominantly associated with p65 protein (lane 7 in Fig. 3B and lane 15 in Fig. 3C) but not with p50 protein (lane 6 in Fig. 3B and lane 14 in Fig. 3C). In phorbol ester-treated HeLa cells (Fig. 3C), Myo/V1 co-immunoprecipitated with c-Rel and p65 protein (lanes 11 and 12 in Fig. 3C) compared with p50 protein (lane 13 in Fig. 3C).


View larger version (61K):
[in this window]
[in a new window]
  		Fig. 3.   Co-immunoprecipitation of NFkappa B with Myo/V1 protein. A, recombinant NFkappa B proteins were incubated separately with immobilized histidine-tagged Myo/V1 protein (bound to nickel resin) and were washed several times with 1 M NaCl. The bound proteins were eluted and immunoblotted with respective NFkappa B antibodies. Lane 1, empty nickel resin beads incubated with p65Delta protein; lane 2, Myo/V1-bound nickel resin beads incubated with p65Delta protein; lane 3, Myo/V1-bound nickel resin incubated with c-Rel (GST-c-Rel; ~75 kDa); lane 4, Myo/V1-bound nickel resin incubated with the p52 protein (homologue of p50; GST-p52; ~80 kDa). B, cellular extracts from HeLa cells treated with TNF plus CHX (lanes 5-7) and diluent (lanes 8-10) were immunoprecipitated with IgG, p50, and p65 antibodies, and the bound proteins were eluted and immunoblotted for Myo/V1. C, cellular extracts from HeLa cells treated with phorbol ester (lanes 11-13) and AdMyo/V1 (lanes 14 and 15) were immunoprecipitated with p50, p65, and c-Rel antibodies, and the bound proteins were eluted and immunoblotted for Myo/V1.

Myo/V1 Promotes the Formation of p50-p50 Homodimers from Monomeric p50 Proteins in Vitro-- Because our earlier studies indicated that Myo/V1 disrupts and induces the formation of new NFkappa B-DNA complexes (3) and can physically interact with NFkappa B proteins in vitro and in vivo (Fig. 3), we designed a detailed study to identify the role of Myo/V1 in altering the specific NFkappa B dimers in vitro. For this purpose, we initially studied the effect of Myo/V1 on monomeric NFkappa B proteins. NFkappa B proteins, p50, and p65 have low affinity to form homodimers among themselves, and a majority of the proteins remain monomeric without binding to kappa B DNA. However, when incubated together, they exhibit high affinity to its heterologous partner and they form heterodimers very easily. Purified recombinant p50 protein and truncated p65Delta protein (from Dr. Gaurishankar Ghosh) was used for these studies. First, monomeric p50 proteins were mixed at very low concentrations (2.5 ng in 50 µl; 2 nM) with Myo/V1 (0-100 ng) and the formation of p50-p50 homodimers were studied using gel-shift assay (lanes 1-5 in Fig. 4A). Similarly, monomeric p65Delta proteins were mixed at very low concentrations (0.5 µg in 50 µl; 7 µM) with Myo/V1 (0-100 ng), the formation of p65Delta -p65Delta homodimers were studied, and the effect of Myo/V1 was studied (lanes 6-10 in Fig. 4A). Although the addition of Myo/V1 (0-100 ng) led to an increased formation of p50-p50 homodimers (lanes 1-5 in Fig. 4A), there was no enhanced formation of p65Delta -p65Delta homodimers (lanes 6-10 in Fig. 4A). We additionally tested the monomeric p65Delta proteins with higher concentrations of Myo/V1 (0-1500 ng), which also did not show any formation of additional p65Delta -p65Delta homodimers (data not shown). These results indicate that Myo/V1 actively promotes the formation of p50-p50 homodimers by dynamically interacting with the p50 subunit of NFkappa B. Although Myo/V1 was found to be physically associated with p65 and its homologues in NFkappa B-activated HeLa cells (Fig. 3), we do not observe the active promotion of p65-p65 homodimers by Myo/V1 in vitro.


View larger version (62K):
[in this window]
[in a new window]
  		Fig. 4.   Myo/V1 promotes the formation of p50-p50 homodimers from monomeric p50 proteins and converts NFkappa B p50-p65 heterodimers to p50-p50 and p65-p65 homodimers in vitro. A, GSA showing the effect of Myo/V1 on monomeric NFkappa B proteins. Increasing concentrations of Myo/V1 (0-100 ng in 25-ng increments) were added to p50 (lanes 1-5; 2.5 ng in 50 µl) and p65 proteins (lanes 6-10; 0.5 µg in 50 µl) separately, and kappa B-DNA binding activity was measured. Lanes 1 and 6 consist of p50-p50 and p65Delta -p65Delta homodimers, respectively, without Myo/V1. In lanes 2-5 and in lanes 7-10, increasing amounts of Myo/V1 (0-100 ng) were added. B, GSA showing the effect of Myo/V1 on preformed NFkappa B p50-p65Delta heterodimers. Increasing concentrations of Myo/V1 were added to preformed p50-p65Delta heterodimers, and kappa B-DNA binding activity was measured. p50 and truncated p65Delta protein were incubated to form p50-p65Delta heterodimers. To serve as a reference, preformed p50-p50 homodimers, p50-p65Delta heterodimers, and p65Delta -p65Delta homodimers are shown in lanes 1, 2, and 12. Increasing concentrations of Myo/V1 protein were added to preformed heterodimers in lanes 3-11. The subtle upward shift of the protein-DNA complex in lanes 3-5 is indicated by parallel arrows. Arrows in lanes 9-11 denote the freed p65Delta subunits forming p65Delta -p65Delta homodimers. C, GSA showing the effect of NFkappa B antibodies on Myo/V1-generated NFkappa B dimers. Increasing concentrations of Myo/V1 were added to preformed p50-p65Delta heterodimers (lanes 1-3), and p50 (lanes 4-6) and p65 antibodies (lanes 7-9) were added. ss, supershifted complex. D, GSA showing the effect of NFkappa B antibodies on Myo/V1-generated NFkappa B dimers with excess p65Delta protein. Increasing concentrations of Myo/V1 were added to preformed p50-p65Delta heterodimers with 100-fold excess p65Delta protein (lanes 1-3), and p50 (lanes 5-7) and p65 antibodies (lanes 9-11) were added. ss, supershifted complex. These results are representative of at least three different experiments.

Myo/V1 Converts NFkappa B p50-p65 Heterodimers to p50-p50 and p65-p65 Homodimers in Vitro-- Because Myo/V1 promoted the formation of p50-p50 homodimers from monomeric p50 proteins, we tested its effect on p50-p65Delta heterodimers. Three different experiments were conducted to study the effect of Myo/V1 (Fig. 4, B-D).

First, an equimolar mixture of p50 and p65Delta proteins (16 pmol each) were allowed to preform p50-p65Delta heterodimers, and the effect of Myo/V1 (4-56 pmol) on these dimers was studied by GSA. The results of this experiment is shown in Fig. 4B, and the effects of NFkappa B antibodies on Myo/V1-generated dimers is shown in Fig. 4C. Because p50 has higher affinity with p65 than to itself, the formation of p50-p65Delta heterodimers under basal conditions (Fig. 4B, lane 2) was expected. The preformed p50-p65Delta heterodimers migrated at a location (lane 2 in Fig 4B) in between the p50-p50 (lane 1 in Fig. 4B) and p65Delta -p65Delta homodimers (lane 12 in Fig. 4B) in the GSA, and this observed subtle difference in the mobility between these dimers is similar to that previously described (43, 51, 52). Because of the deletion of the carboxyl terminus of p65 protein, the truncated p65Delta -p65Delta homodimers (~31-kDa dimers) migrate faster (lane 12 in Fig. 4B) than p50-p50 homodimers (lane 1 in Fig. 4B). With increasing concentrations of Myo/V1 (lanes 4-11 in Fig. 4B), we observed a subtle upward shift in the mobility of the NFkappa B dimers, reaching a position occupied by the p50-p50 homodimers. This gradual upward shift suggests that Myo/V1 converted p50-p65Delta heterodimers to p50-p50 homodimers (lanes 4-11 in Fig. 4B) in a dose-dependent fashion. 100% conversion (lane 6 in Fig. 4B) occurred when the ratio of Myo/V1 to p50-p65Delta heterodimers reached 1 (16 pmol). At a lower ratio, the unconverted p50-p65Delta heterodimers were still present (lane 3 in Fig. 4B) in the reaction. Furthermore, at high concentrations of Myo/V1 (32-56 pmol), p65Delta -p65Delta homodimers started to appear (arrows in lanes 9-11 in Fig. 4B) in these reactions. Because Myo/V1 does not actively promote the formation of p65Delta -p65Delta homodimers (lanes 6-10 in Fig. 4A), it is possible the p65Delta subunits, freed from the splitting of the p50-p65Delta heterodimers, accumulated to reach high concentrations and may have self-associated to form p65Delta -p65Delta homodimers. This is not surprising, because p65 exhibits lowest affinity to itself among NFkappa B subunits; hence, the p65-p65 homodimers are formed only when they accumulate at high concentrations (43).

Later, to further confirm the nature of Myo/V1-generated dimers, the effect of NFkappa B antibodies on these complexes was studied (Fig. 4C). The p50-p65Delta heterodimers were pre-assembled at equimolar ratio as previously described, and Myo/V1 was added at two (100 and 400 ng) concentrations (lanes 2 and 3 in Fig. 4C). These reactions were performed in triplicate for p50 and p65 antibody supershifts (lanes 5, 6, 8, and 9 in Fig 4C). As expected, we observed both an upward shift in the mobility of Myo/V1-shifted dimers occupying the position of p50-p50 homodimers (lanes 2 and 3 in Fig. 4C) as well as an increased formation of p50-p50 homodimers with increasing amounts of Myo/V1 (lanes 2 and 3 in Fig. 4C) in these reactions. Lanes 4-6 confirm that these dimers have p50 proteins as revealed by p50 antibody supershifted complexes. Lanes 7-9 exhibit the inhibitory effects of p65 antibody on Myo/V1-generated dimers. Because the p65 antibody exhibits inhibitory activity on p65 proteins (Rel DNA binding domain antibodies are not supershiftable), the formation of heterodimers as well as the conversion to homodimers was also affected (lanes 7-9). Hence, the subtle upward shift observed in lanes 2 and 3 was not observed in lanes 8 and 9. Lanes 8 and 9 contain a mixture of p50-p50 homodimers and p50-p65Delta heterodimers. Close examination of the migratory patterns and the levels of these dimers (lanes 8 and 9 in Fig. 4C) reveals that, in the presence of p65 antibody, Myo/V1 promoted the formation of p50-p50 homodimers from the residual free monomeric p50 proteins, although at a reduced level. The splitting of the heterodimers as observed in lanes 2 and 3 did not occur in these reactions (lanes 8 and 9) because of the presence of p65 antibody. The NFkappa B dimers that appear in lanes 7-9 are predominantly p50-p50 homodimers, as evidenced by its location.

To further confirm the chaperone functions of Myo/V1, we conducted another experiment (Fig. 4D), where the amount of p65Delta was kept excess by 100-fold to that of p50 so that, in addition to the preformed p50-p65Delta heterodimers, free p65Delta proteins will be present in the reaction. The effect of Myo/V1 (lanes 1-3 in Fig. 4D), and the effect of NFkappa B antibodies on these Myo/V1-shifted complexes were studied (lanes 6-8 and 10-12 in Fig. 4D). The rationale for this experiment is that, when the p50-p65 heterodimers are split by Myo/V1, there will be a competition among the released monomeric proteins to form either homodimers or heterodimers. With excess p65 protein in the reaction and because of its high affinity toward p50 protein to form heterodimers (43), there will be a continuous formation of new p50-p65 heterodimers as the old heterodimers are being converted by Myo/V1. Thus, in this experiment Myo/V1-generated "intermediate products" can be identified. The p50-p65Delta heterodimers were pre-assembled at 1:100 ratios, and Myo/V1 was added at two (100 and 400 ng) concentrations (lanes 2 and 3 in Fig. 4D). These reactions were performed in triplicate for p50 and p65 antibody supershifts (lanes 5-7 and 9-11 in Fig. 4D). As expected (shown in Fig. 4D), both heterodimers and homodimers were formed when Myo/V1 was present at high concentrations with excess p65 (lane 3). The complete subtle upward shift observed in lane 3 of Fig. 4C was not similarly observed in lane 3 of Fig. 4D, strongly indicating the presence of both heterodimers and homodimers. The presence of both of these dimers is more clearly seen in lanes 7 and 11. Additionally, we also observed a simultaneous reduction in p65Delta -p65Delta homodimers (lanes 1-3) with the addition of Myo/V1. Because Myo/V1 does not have any direct effect on p65 per se (lanes 6-10 in Fig. 4A), the reduction in p65Delta -p65Delta homodimers in lanes 1-3 is a result of its incorporation into p50 protein in the reaction to form p50-p65Delta heterodimers. Furthermore, the absence of p50-p65Delta heterodimers in lanes 6 and 10 and the presence of these dimers in lanes 7 and 11 correlate with the reduction of p65Delta -p65Delta homodimers in lanes 7 and 11. Lanes 5-7 confirm that the Myo/V1-generated dimers have p50 proteins, as revealed by supershifted complexes. Because of excess p65, p50 antibody supershifts did not occur completely. Because the p65 antibody used in lanes 9-11 exhibits inhibitory activity on p65 proteins, the complete conversion of heterodimers to homodimers is affected. Thus, these results further confirm the chaperone functions of Myo/V1 in promoting NFkappa B homodimers and the formation of p50-p65Delta heterodimers is an indirect event promoted by the chaperone functions of Myo/V1 on p50.

Overexpression of Myo/V1 Changes the Ratio of Activated NFkappa B Dimers in Vivo in Favor of p50-p50 Homodimers-- To further confirm our in vitro results, in vivo studies were conducted to identify the role of Myo/V1 in NFkappa B homodimer generation. For this purpose, a strategy of adenovirus-mediated overexpression of Myo/V1 was chosen to exploit the inherent activation of NFkappa B heterodimers by recombinant adenoviral vectors (57-59). Thus, Myo/V1 overexpressing recombinant adenovirus is expected to alter the composition of activated NFkappa B dimers induced by its viral vector backbone (57-59). HeLa cells were infected with recombinant adenoviruses expressing Myo/V1 (AdMyo/V1) and beta -galactosidase (Adbeta gal), and nuclear extracts were prepared 12 h after infection. kappa B DNA binding reactions (Fig. 5A) were conducted with three high affinity NFkappa B dimer-specific oligos, and the levels of individual NFkappa B dimers were quantified (Fig. 5, B and C). Identical amounts of kappa B oligos (25,000 cpm) with similar specific activities were incubated with identical amounts of nuclear extracts, and the resulting NFkappa B-DNA complexes were fractionated on the same gel before autoradiography.


View larger version (74K):
[in this window]
[in a new window]
  		Fig. 5.   Myo/V1 changes the ratio of NFkappa B dimers in vivo in favor of p50-p50 homodimers. A, GSA showing the effect of Myo/V1 on in vivo generated NFkappa B dimers. HeLa cells were infected with AdMyo/V1 or Adbeta gal recombinant adenoviruses at a multiplicity of infection of 10. Twelve hours after infection, nuclear extracts were prepared and GSAs were conducted with three high affinity NFkappa B dimer-specific oligonucleotides (kappa B#seqB for p50-p50 homodimers; kappa B#u-iNOS for p65-p65 homodimers; IgGkappa B oligonucleotide for p50-p65 heterodimers) (lanes 1-6). Supershift experiments with NFkappa B p50 and p65 antibodies were conducted to confirm the nature of the NFkappa B dimers (lanes 7-15). p50 supershift complexes are indicated by *, and p65 supershift complexes are indicated by arrows. B, quantitative comparison of NFkappa B dimers between Adbeta gal and AdMyo/V1. The bar graph shows the -fold change in the levels of individual NFkappa B dimers in relation to Adbeta gal-infected HeLa cells. C, relative levels of NFkappa B dimers in Adbeta gal- and AdMyo/V1-infected cells. The bar graph shows the NFkappa B dimer ratio in relation to p50-p65 heterodimers in Adbeta gal- and AdMyo/V1-infected HeLa cells. These results are representative of six different experiments, conducted four times at a multiplicity of infection of 10 and twice at a multiplicity of infection of 50.

Results show that overexpression of AdMyo/V1 enhanced the generation of p50-p50 (lane 2 in Fig. 5A) and p65-p65 (lane 4 in Fig. 5A) homodimers compared with the control Adbeta gal (lanes 1 and 3 in Fig. 5A). Interestingly, p50-p65 heterodimers are less abundant in AdMyo/V1 compared with the Adbeta gal-overexpressing cells (lanes 5 and 6 in Fig. 5A). Thus, the observation of a simultaneous decrease in the levels of p50-p65 heterodimers and an increase in p50-p50 and p65-p65 homodimers suggests a conversion from heterodimers to homodimers (Fig. 5B). Moreover, an unequal quantitative shift (Fig. 5B) occurred between p50-p50 homodimers and p50-p65 heterodimers in Myo/V1-overexpressing cells. Although the levels of p50-p50 homodimers were elevated by 70%, the p50-p65 heterodimers declined by 26% (Fig. 5B). This observation suggests that Myo/V1, in addition to generating the p50-p50 homodimers from the p50-p65 heterodimeric substrates, might directly generate nascent p50-p50 homodimers from other in vivo substrates, further confirming our previous in vitro results (Fig. 4B). Furthermore, analysis of the relative levels of NFkappa B dimers (Fig. 5C) in AdMyo/V1-infected cells (p50-p65:p50-p50:p65-p65; 1.0:1.3:0.5) revealed that the levels of p50-p50 homodimers exceeded the levels of p50-p65 heterodimers compared with Adbeta gal (1.0:0.55:0.2). Because p50-p50 homodimers possess transcriptionally repressive activity (17-22), the observed shifts in the NFkappa B dimer ratio in Myo/V1-overexpressing cells might have repressive effects on the NFkappa B-mediated transcription process.

Antibody supershift experiments and heterologous kappa B oligo chase experiments (data not shown) confirmed the nature of NFkappa B dimers (lanes 7-15 in Fig. 5A) binding to the kappa B oligos kappa B#SeqB, kappa B-Igkappa , and kappa B#u-iNOS. However, the p50 antibody supershifting the NFkappa B complexes bound to kappa B#u-iNOS oligo (lane 11 in Fig. 5A) was unexpected. We believe this is because of "antibody-induced effect" rather than residual p50-p65 heterodimers binding to these kappa B oligos. The p50 antibody after binding to a p50-p65 heterodimer could change the affinity of the "supershifted heterodimeric ternary complex" now to recognize and bound to a otherwise p65-p65 homodimer specific oligo. Although antibodies used in gel-shift assays are generally described as "supershifting antibodies," these antibodies change the affinity of homo- and heterodimers and thereby affect their binding to kappa B sites. Evidence of these artifacts is seen in lanes 12 and 15 where increased (lane 12) and decreased (lane 15) binding is observed after the antibody was added. Therefore, as described previously (44, 45) without the NFkappa B antibodies, kappa B#seqB and kappa B#u-iNOS oligos exhibit high affinity and exclusive specificity toward p50-p50 and p65-p65 homodimers. Additionally, we conducted heterologous kappa B oligo chase experiments (kappa B#u-iNOS-bound complexes chased with 100× cold kappa B#SeqB and kappa B-Igkappa oligos), and the results revealed that Myo/V1-overexpressing HeLa cells still produced higher levels of p65-p65 homodimers compared with Adbeta gal (data not shown). Additional chase experiments (kappa B#SeqB complexes chased with 100× cold kappa B#u-iNOS and kappa B-Igkappa oligos; kappa B-Igkappa complexes chased with 100× cold kappa B#50-2 and kappa B#u-iNOS oligos) were done, and the results were exactly the same as in Fig. 5A (data not shown).

Myo/V1 Represses NFkappa B-mediated Transcription Process-- To identify the functional relevance of Myo/V1 with respect to NFkappa B dimers, we studied the role of Myo/V1 on NFkappa B-mediated transcription. HeLa cells were cotransfected with pkappa B-tk-luc, p65 pRSV-RelA, and pcDNA-AM1.1-Myo/V1 expression vector. Forty-eight hours after transfection, HeLa cells were harvested and lysed and luciferase enzyme activity was measured. The results (Fig. 6) show that overexpression of Myo/V1 significantly reduced the NFkappa B-mediated transcription by 42% (p <=  0.05) on p65-mediated luciferase reporter activity. Because p50-p65 heterodimers are not available for Myo/V1 to act, and because Myo/V1 does not actively promote p65-p65 homodimers per se, the observed inhibition is probably the result of the initial generation of abundant p50-p50 homodimers (Myo/V1 acting on p50-p105 complexes) that are well known for transcriptional repression of their target genes (17-22).


View larger version (25K):
[in this window]
[in a new window]
  		Fig. 6.   Myo/V1 represses NFkappa B-mediated transcription process. HeLa cells were cotransfected with constant amounts of tk-kappa B2-luciferase reporter (500 ng) and pRSV-RelA (500 ng). Myo/V1 or beta -gal control expressing plasmid (200 ng) was cotransfected, and, 48 h later, cells were harvested and lysed and luciferase enzyme activity was measured. Luciferase activity was normalized for protein concentration and transfection efficiency. Transfection experiments were performed four times, and the data are shown as -fold change over control cells. Comparison of two groups was done by unpaired Student's t test. All statistical analysis was performed with SigmaStat (SPSS Inc.). Significance was accepted at p < 0.05.

Three-dimensional Structural Alignment of Myo/V1 with Rel-interacting Ankyrin Repeats of Ikappa Balpha Reveals the Potential Chaperone Functions of Myo/V1 on NFkappa B-- To correlate the observed chaperone functions of Myo/V1 with its structural domains, we conducted the three-dimensional superimposition analysis (60) using the three-dimensional NMR structure of Myo/V1 (Fig. 7A) (11, 12) and the three-dimensional structure of Ikappa Balpha (Fig. 7B) (13, 14), where NFkappa B-interacting domains were well characterized. The superimposed Calpha traces of Myo/V1 with Ikappa Balpha (Fig. 7, C and D) show that entire Myo/V1 aligned with ankyrin repeats 3-6 of Ikappa Balpha protein, further confirming our earlier primary structural homologies with Ikappa Balpha (3). This finding is highly significant because these specific ankyrin repeats of Ikappa Balpha interact with the Rel domain of p50 and p65 subunits (Fig. 7, C and D) that are known for dimerization and kappa B DNA binding. Moreover, the ankyrin repeats 1 and 2 of Ikappa Balpha (aa 67-142), which mask the NLS signal of p65, the amino-terminal SRD (aa 1-66 of Ikappa Balpha ), and the carboxyl-terminal acidic PEST domain (aa 281-317) that is responsible for degradation of Ikappa Balpha , are all absent in the Myo/V1 protein. Thus, the fact that Myo/V1 resembles only the Rel-interacting ankyrin repeat domains of Ikappa Balpha (AR 3-6) strongly suggests that Myo/V1 might similarly interact with the Rel DNA binding domain of NFkappa B but, unlike Ikappa Balpha , Myo/V1 might mediate its chaperone functions in a zipper-like fashion using the terminal residues of its three finger loops (Fig. 7, C and D). One of the overlooked functions of Ikappa Balpha is its use of these ankyrin repeats (AR 3-6) to assemble the inactive NFkappa B dimers in the cytoplasm. Similar to Myo/V1, Ikappa Balpha might also possess zipper chaperone function; however, it is only used to assemble the inactive NFkappa B dimers in the cytoplasm. Because of its other NLS masking ankyrin repeats (repeats 1 and 2) and SRD domain, it behaves as an inhibitor or a carrier of NFkappa B. Because of the observed similarity in Rel-interacting ankyrin repeats, one could envision that Ikappa B and Myo/V1 proteins could behave as lock and key of NFkappa B dimers in the mammalian cell.


View larger version (36K):
[in this window]
[in a new window]
  		Fig. 7.   Three-dimensional structural homologies between Myo/V1 and Ikappa Balpha . The three-dimensional superimposition analysis (60) was done on the Dali server (www2.ebi.ac.uk/dali/fssp/). The Calpha traces of Myo/V1 (A) and Ikappa Balpha (B) were superimposed (C), viewed by Rasmol plug-in software, and captured. D, primary sequence alignment of Myo/V1 with Ikappa Balpha using the three-dimensional superimposition analysis data. Purple and dark blue colored residues in Ikappa Balpha are known to interact with p50 and p65 proteins, respectively (13, 14). Red AR1-6 denote ankyrin repeats of Ikappa Balpha , and purple AR1-3 denote ankyrin repeats of Myo/V1. PEST is the degradation domain of Ikappa Balpha .


    DISCUSSION
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

Myo/V1 was first identified as an up-regulated intracellular protein in pathophysiological conditions (1, 4-6) such as human heart failure, as well as during early organ developmental processes such as in postnatal mammalian cerebellum (2, 4, 8, 10). However, later it was identified to express in every mammalian organ and cell type. Moreover, Myo/V1 is an evolutionarily conserved protein from multicellular organisms to mammals (Fig. 8). Among mammals it shows 97% homology, and with invertebrates it exhibits 67% homology. Putative nuclear import and export signals as well as potential phosphorylation sites were mostly conserved between invertebrates and vertebrates (Fig. 8). Our three-dimensional structural alignment studies (Fig. 7C) further revealed that Myo/V1 possessed only Rel domain-interacting ankyrin repeats and resembles a truncated form of Ikappa Balpha protein without the SRD, NLS masking, and PEST degradation domains (Fig. 7D).


View larger version (42K):
[in this window]
[in a new window]
  		Fig. 8.   Evolutionary conservation of Myo/V1. Sequences of Myo/V1 from various species were identified in the GenBankTM database (rat, U21661; human, AC015987; mouse, AAA86719; chicken, BAA05379; Drosophila, AAF48915; Caenorhabditis elegans, AAA96086; marine sponge, CAC38782) and aligned using CLUSTAL W alignment program. Potential phosphorylation and nuclear import (aa 36-51) and export (aa 52-60) signals are highlighted. Nuc. Imp. Signal, nuclear import signal; Nuc. Exp. Sig., nuclear export signal; GSK3/CK-I, glycogen synthase kinase 3/casein kinase I; PKC, protein kinase C; CK-II, casein kinase II.

Results presented in this study indicate that, under basal conditions, cellular Myo/V1 predominantly present in the cytoplasm and probably associates with cytoskeletal structures (Fig. 1) similar to Ikappa Balpha (61, 62). Additionally, low levels of Myo/V1 are also present in the nucleus (Fig. 1C) of unstimulated HeLa cells and in other cell types such as Jurkat T cells and rat neonatal cardiac myocytes.2 Our studies also demonstrated that, upon stimulation with TNF, Myo/V1 relocates within the cytoplasm (Fig. 1B) and further translocates to the nucleus during sustained induction of NFkappa B (Figs. 1B and 2B). Because Myo/V1 possesses both nuclear import and export signals (Fig. 8), it is expected that Myo/V1 might shuttle between cytoplasm and nucleus similar to Ikappa B family of proteins (32-36). Co-immunoprecipitation studies showed that, although Myo/V1 interacts with all NFkappa B proteins in vitro, it remains physically associated only with p65 and c-Rel proteins in vivo (Fig. 3). The differences between in vitro and in vivo results might also reflect the potential function of Myo/V1 protein. For example, Myo/V1 may interact dynamically with p50 proteins in vivo in a transient fashion to mediate its zipper chaperone function; however, it remains physically associated with p65 or its homologue c-Rel protein to prevent them from reassociating with p50. In vitro NFkappa B interaction studies indicated that Myo/V1 can generate p50-p50 homodimers from monomeric p50 proteins and can convert the preformed p50-p65 heterodimers into p50-p50 and p65-p65 homodimers (Figs. 4 and 9A). Compared with control Adbeta gal, overexpression of AdMyo/V1 resulted in an increase in both p50-p50 and p65-p65 homodimers exceeding the levels of p50-p65 heterodimers (Fig. 5). A simultaneous decrease in the levels of p50-p65 heterodimers was also observed, suggesting a conversion from transactivating heterodimers to transcriptionally repressive homodimers (17-25). However, the observation of disproportionate increase in the levels of p50-p50 homodimers compared with the decreased levels of heterodimers (70% increase versus 26% decrease) raises the possibility that Myo/V1 might also generate p50-p50 homodimers from other inactive NFkappa B substrates. Because a majority of the Myo/V1 is localized in the cytoplasm, it could very well be involved in the activation of p50-p50 homodimers by acting on p50-p105 substrates (63) in vivo (Fig. 9B). Alternatively, Myo/V1 could assemble the p50-p50 homodimers from free monomeric p50 proteins in the cytoplasm similar to the conditions mentioned in Fig. 4A. Additionally, Myo/V1 could act on any p50 subunit containing complexes (p50-p65, p50-c-Rel, p50-RelB, and "p50-non-NFkappa B" dimers) in the nucleus and further generate the transcriptionally repressive p50-p50 homodimers (Fig. 9B). In accordance with these observations, overexpression of Myo/V1 also resulted in significantly reduced NFkappa B-mediated luciferase reporter gene expression (Fig. 6), which is probably a result of the generation of p50-p50 homodimers.


View larger version (33K):
[in this window]
[in a new window]
  		Fig. 9.   Model for zipper chaperone function of Myo/V1 (A) and potential in vivo NFkappa B substrates for Myo/V1 protein (B). Model shows potential involvement of Myo/V1 in multiple NFkappa B activation pathways in HeLa cells. B, 1, potential involvement of Myo/V1 in generating p50-p50 homodimers from p50-p105 complexes, and 2, conversion of heterodimers to homodimers by Myo/V1 during sustained activation of NFkappa B. HDAC, histone deacetylase.

Although we observed an increased level of p65-p65 homodimers during AdMyo/V1 overexpression (Fig. 5A), and Myo/V1 being physically associated with p65 and its homologues (Fig. 3), in vitro interaction experiments (Fig. 4A) do not suggest an active role for Myo/V1 in the generation of p65-p65 homodimers. Moreover, in overexpression of Myo/V1 in HeLa cells through transient transfection methods (Fig. 6), where "active p50-p65 heterodimers" are not available for Myo/V1 to act upon, we only observed an inhibition of kappa B driven luciferase reporter activity. If Myo/V1 would have actively promoted the generation of p65-p65 homodimers in these cells, we should have observed an increased kappa B-luciferase reporter activity during Myo/V1 overexpression. Because Myo/V1 does not retain or sequester p65 in the cytoplasm2 under basal conditions (Fig. 3B), the observed inhibition of kappa B-luciferase reporter activity is the result of the active generation of p50-p50 homodimers by Myo/V1, as observed in our in vitro and in vivo experiments (Figs. 4 and 5). Therefore, we believe the increased generation of p65-p65 homodimers during AdMyo/V1 expression is an indirect effect of the conversion of p50-p65 heterodimers by Myo/V1 and the physical association of Myo/V1 with p65 is probably to prevent the p65 from reassociating with p50 (Fig. 9A).

Even though our studies indicate that Myo/V1 could favor the active generation of NFkappa B homodimers in HeLa cells, it is possible that, under certain scenarios (similar to conditions mentioned in Fig. 4D), Myo/V1 could indirectly induce the formation of NFkappa B heterodimers in other cell types. For example, Myo/V1 could potentially act on inactive p50-p65-Ikappa Balpha substrate complexes in the cytoplasm and generate active NFkappa B heterodimers in immune cells. Because Myo/V1 has been identified as a "severe combined immunodeficiency complementing gene" (GenBankTM accession no. D78188), and because this protein is also found in the nuclear extracts of phorbol ester-treated Jurkat T cells,2 the potential role of Myo/V1 in the activation of other NFkappa B dimers is highly likely.

The data presented in this study were further strengthened when, from previously published independent studies (2, 64-66), we identified a strong temporal relationship between the intracellular levels of Myo/V1 and NFkappa B activation in vivo in mammalian organs. Myo/V1 was found to occur at elevated levels in failing human hearts (1, 4-6) and found to be transiently elevated in postnatal mammalian cerebellum (2, 7). Interestingly, NFkappa B dimers were also found to be activated in failing human hearts2 (67) as well as in developing postnatal cerebellum (64-66) during this period. Specifically, in postnatal cerebellum, the intracellular level of Myo/V1 protein was found to rise at the 2nd day, peak at the 7th day, and rapidly decrease by the 12th day (2). Similarly, independent studies have reported the transient activation of NFkappa B dimers begin to occur around postnatal day 2, peaking at the 7th day, and declining by 12th day in rat (64, 65) and mouse cerebellum (66). This strong temporal observation that the intracellular levels of Myo/V1 being elevated exactly at the same time during NFkappa B dimer activation and its decline during the disappearance of NFkappa B dimers in postnatal cerebellum further highlights the important potential role of Myo/V1 even in initial NFkappa B activation. The earlier observation of disproportionate increase in the levels of p50-p50 homodimers compared with the decreased levels of heterodimers in AdMyo/V1-infected cells (Fig. 5) also raises the possibility that Myo/V1 might be involved in the initial activation of p50-p50 homodimers in vivo (Fig. 9B). Therefore, the results presented in this study strongly suggest that not only Myo/V1 is involved in converting heterodimers into homodimers during sustained NFkappa B activation, it could potentially be involved in the initial activation of NFkappa B dimers. The recent identification that entire NFkappa B machinery (NIK, IKKs, Ikappa Balpha , ubiquitination, and proteasome) is shuttling (68, 69) between cytoplasm and the nucleus of resting mammalian cells (32-35) and the observation of NFkappa B activation without Ikappa B degradation (70, 71) changes the central tenet of NFkappa B signaling mechanism. In this changed scenario, several alternate Ikappa B-independent pathways (70-72) have been proposed for NFkappa B activation, and Myo/V1 could potentially be involved in such pathways.

The identification of Myo/V1 as a NFkappa B zipper chaperone (Fig. 9A) to shift the NFkappa B dimer ratio from transcriptionally active heterodimers to transcriptionally repressive homodimers is also highly significant. In fact, in many biological scenarios like B lymphocyte cell differentiation (40-42), lipopolysaccharide tolerance (73), T-lymphocyte anergy (74), and chronic TNF exposure to mouse myocardium (75), the activated NFkappa B dimers are known to change both quantitatively and qualitatively during these events. For example, during B lymphocyte cell differentiation (40-42), dynamic exchange of NFkappa B subunits are known to occur among the activated NFkappa B dimers resulting in altered gene expression appropriate for the stage of differentiation. During endotoxin tolerance in monocytes (73), T-lymphocyte anergy (74), and chronic TNF exposure to mouse myocardium (75), the levels of p50-p50 homodimers are known to increase during late stages of these events, suggesting a dynamic qualitative and quantitative change in the activated NFkappa B dimers. Moreover, In human sepsis, large amounts of p50-p50 homodimers exceeding the levels of p50-p65 heterodimers were observed in monocytes of non-survivors compared with the survivors, further suggesting an important role for NFkappa B dimer ratio in the pathophysiology of sepsis (76). Furthermore, the NFkappa B dimer ratio has been shown to determine the ultimate level of target gene expression (18, 22). NFkappa B-mediated gene transcription has been proposed in models of myocardial diseases (3, 77, 78). Taken together with the previous finding that elevated levels of Myo/V1 are found in failing mammalian hearts (5, 6), this study collectively suggests that Myo/V1 might play a significant NFkappa B regulatory role at the transcriptional level during chronic pathophysiological conditions such as human heart failure.

    ACKNOWLEDGEMENTS

We thank Dr. Gaurishankar Ghosh (University of California, San Diego) for generously providing the recombinant p65Delta protein, Stacey L. Walker for technical assistance, and Dr. Douglas L. Mann for continued support and critically reviewing the manuscript.

    FOOTNOTES

* This work was supported in part by Grant-in-aid 0050786Y (to N. S.) from the American Heart Association, Texas affiliate.The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Dagger Supported by Deutsche Forschungsgemeinschaft Grant KN521/1-1. Present address: Dept. of Anesthesiology and Intensive Care Medicine, University of Bonn, Sigmund-Freud-Strasse 25, 53105 Bonn, Germany.

§ Present address: Dept. of Internal Medicine, University of Texas Southwestern Medical Center, Dallas, TX 75235.

Present address: Cardiovascular Research Inst., Dept. of Medicine, University of Medicine and Dentistry at New Jersey, Newark, NJ 07103.

|| To whom correspondence should be addressed: Winters Center for Heart Failure Research, 6565 Fannin St., MS524, Houston, TX 77030. Tel.: 713-441-1243; Fax: 713-441-1252;E-mail: nats@bcm.tmc.edu.

Published, JBC Papers in Press, April 23, 2002, DOI 10.1074/jbc.M202937200

2 N. Sivasubramanian, unpublished data.

    ABBREVIATIONS

The abbreviations used are: Myo/V1, myotrophin or V-1; TNF, tumor necrosis factor-alpha ; CHX, cycloheximide; GSA, gel-shift assay; NFkappa B, nuclear factor of kappa B; Ikappa Balpha , inhibitor of kappa B-alpha ; Tricine, N-tris(hydroxymethyl)methylglycine; aa, amino acid(s); FITC, fluorescein isothiocyanate; DAPI, 4,6-diamidino-2-phenylindole; SRD, signal response domain; oligo, oligonucleotide; NLS, nuclear localization signal; NIK, NFkappa B-inducing kinase; IKK, Ikappa Balpha kinase.

    REFERENCES
TOP
ABSTRACT
INTRODUCTION
EXPERIMENTAL PROCEDURES
RESULTS
DISCUSSION
REFERENCES

1. Sen, S., Kundu, G., Mekhail, N., Castel, J., Misono, K., and Healy, B. (1990) J. Biol. Chem. 265, 16635-16643[Abstract/Free Full Text]
2. Taoka, M., Yamakuni, T., Song, S. Y., Yamakawa, Y., Seta, K., Okuyama, T., and Isobe, T. (1992) Eur. J. Biochem. 207, 615-620[Medline] [Order article via Infotrieve]
3. Sivasubramanian, N., Adhikary, G., Sil, P. C., and Sen, S. (1996) J. Biol. Chem. 271, 2812-2816[Abstract/Free Full Text]
4. Anderson, K. M., Berrebi-Bertrand, I., Kirkpatrick, R. B., McQueney, M. S., Underwood, D. C., Rouanet, S., and Chabot-Fletcher, M. (1999) J. Mol. Cell Cardiol. 31, 705-719[CrossRef][Medline] [Order article via Infotrieve]
5. Sil, P., Misono, K., and Sen, S. (1993) Circ. Res. 73, 98-108[Abstract]
6. Sil, P., Mukherjee, D., and Sen, S. (1995) Circ. Res. 76, 1020-1027[Abstract/Free Full Text]
7. Taoka, M., Isobe, T., Okuyama, T., Watanabe, M., Kondo, H., Yamakawa, Y., Ozawa, F., Hishinuma, F., Kubota, M., and Minegishi, A. (1994) J. Biol. Chem. 269, 9946-9951[Abstract/Free Full Text]
8. Song, S. Y., Asakai, R., Kenmotsu, N., Taoka, M., Isobe, T., and Yamakuni, T. (1996) Endocrinology 137, 1423-1428[Abstract]
9. Yamakuni, T., Yamamoto, T., Hoshino, M., Song, S. Y., Yamamoto, H., Kunikata-Sumitomo, M., Minegishi, A., Kubota, M., Ito, M., and Konishi, S. (1998) J. Biol. Chem. 273, 27051-27054[Abstract/Free Full Text]
10. Pennica, D., Shaw, K. J., Luoh, S. M., and Wood, W. I. (1995) Gene (Amst.) 158, 305-306[CrossRef][Medline] [Order article via Infotrieve]
11. Yang, Y., Rao, N. S., Walker, E., Sen, S., and Qin, J. (1997) Protein Sci. 6, 1347-1351[Medline] [Order article via Infotrieve]
12. Yang, Y., Nanduri, S., Sen, S., and Qin, J. (1998) Structure 6, 619-626[Medline] [Order article via Infotrieve]
13. Huxford, T., Huang, D. B., Malek, S., and Ghosh, G. (1998) Cell 95, 759-770[CrossRef][Medline] [Order article via Infotrieve]
14. Jacobs, M. D., and Harrison, S. C. (1998) Cell 95, 749-758[CrossRef][Medline] [Order article via Infotrieve]
15. Baeuerle, P. A., and Baltimore, D. (1996) Cell 87, 13-20[CrossRef][Medline] [Order article via Infotrieve]
16. Pahl, H. L. (1999) Oncogene 18, 6853-6866[CrossRef][Medline] [Order article via Infotrieve]
17. Plaksin, D., Baeuerle, P. A., and Eisenbach, L. (1993) J. Exp. Med. 177, 1651-1662[Abstract/Free Full Text]
18. Brigelius-Flohe, R., Bilgin, B., Eickemeier, S., Hipskind, R., Singh, M., Szamel, M., and Resch, K. (1995) Biofactors 5, 169-174[Medline] [Order article via Infotrieve]
19. Goldring, C. E., Narayanan, R., Lagadec, P., and Jeannin, J. F. (1995) Biochem. Biophys. Res. Commun. 209, 73-79[CrossRef][Medline] [Order article via Infotrieve]
20. Supakar, P. C., Jung, M. H., Song, C. S., Chatterjee, B., and Roy, A. K. (1995) J. Biol. Chem. 270, 837-842[Abstract/Free Full Text]
21. Kastenbauer, S., and Ziegler-Heitbrock, H. W. (1999) Infect. Immun. 67, 1553-1559[Abstract/Free Full Text]
22. Udalova, I. A., Richardson, A., Denys, A., Smith, C., Ackerman, H., Foxwell, B., and Kwiatkowski, D. (2000) Mol. Cell. Biol. 20, 9113-9119[Abstract/Free Full Text]
23. Sheppard, K. A., Rose, D. W., Haque, Z. K., Kurokawa, R., McInerney, E., Westin, S., Thanos, D., Rosenfeld, M. G., Glass, C. K., and Collins, T. (1999) Mol. Cell. Biol. 19, 6367-6378[Abstract/Free Full Text]
24. Ashburner, B. P., Westerheide, S. D., and Baldwin, A. S., Jr. (2001) Mol. Cell. Biol. 21, 7065-7077[Abstract/Free Full Text]
25. Nozaki, S., Sledge, G. W., Jr., and Nakshatri, H. (2001) Oncogene 20, 2178-2185[CrossRef][Medline] [Order article via Infotrieve]
26. Waltner-Law, M., Daniels, M. C., Sutherland, C., and Granner, D. K. (2000) J. Biol. Chem. 275, 31847-31856[Abstract/Free Full Text]
27. Kalkhoven, E., Wissink, S., van der Saag, P. T., and van der Burg, B. (1996) J. Biol. Chem. 271, 6217-6224[Abstract/Free Full Text]
28. Sohur, U. S., Dixit, M. N., Chen, C. L., Byrom, M. W., and Kerr, L. A. (1999) Gene Exp. 8, 219-229
29. Farmer, P. K., He, X., Schmitz, M. L., Rubin, J., and Nanes, M. S. (2000) Am. J. Physiol. 279, E213-E220
30. Nagarajan, R. P., Chen, F., Li, W., Vig, E., Harrington, M. A., Nakshatri, H., and Chen, Y. (2000) Biochem. J. 348, 591-596[CrossRef][Medline] [Order article via Infotrieve]
31. Guttridge, D. C., Mayo, M. W., Madrid, L. V., Wang, C. Y., and Baldwin, A. S., Jr. (2000) Science 289, 2363-2366[Abstract/Free Full Text]
32. Johnson, C., Van Antwerp, D., and Hope, T. J. (1999) EMBO J. 18, 6682-6693[CrossRef][Medline] [Order article via Infotrieve]
33. Carlotti, F., Dower, S. K., and Qwarnstrom, E. E. (2000) J. Biol. Chem. 275, 41028-41034[Abstract/Free Full Text]
34. Malek, S., Chen, Y., Huxford, T., and Ghosh, G. (2001) J. Biol. Chem. 276, 45225-45235[Abstract/Free Full Text]
35. Tam, W. F., Wang, W., and Sen, R. (2001) Mol. Cell. Biol. 21, 4837-4846[Abstract/Free Full Text]
36. Pando, M. P., and Verma, I. M. (2000) J. Biol. Chem. 275, 21278-21286[Abstract/Free Full Text]
37. Karin, M., and Ben-Neriah, Y. (2000) Annu. Rev. Immunol. 18, 621-663[CrossRef][Medline] [Order article via Infotrieve]
38. Schmitz, M. L., Bacher, S., and Kracht, M. (2001) Trends Biochem. Sci. 26, 186-190[CrossRef][Medline] [Order article via Infotrieve]
39. Chen, L., Fischle, W., Verdin, E., and Greene, W. C. (2001) Science 293, 1653-1657[Abstract/Free Full Text]
40. Goldring, C. E., Reveneau, S., Pinard, D., and Jeannin, J. F. (1998) Eur. J. Immunol. 28, 2960-2970[CrossRef][Medline] [Order article via Infotrieve]
41. Liou, H. C., Sha, W. C., Scott, M. L., and Baltimore, D. (1994) Mol. Cell. Biol. 14, 5349-5359[Abstract/Free Full Text]
42. Miyamoto, S., Schmitt, M. J., and Verma, I. M. (1994) Proc. Natl. Acad. Sci. U. S. A. 91, 5056-5060[Abstract/Free Full Text]
43. Kunsch, C., Ruben, S. M., and Rosen, C. A. (1992) Mol. Cell. Biol. 12, 4412-4421[Abstract/Free Full Text]
44. Pan, J., and McEver, R. P. (1995) J. Biol. Chem. 270, 23077-23083[Abstract/Free Full Text]
45. Marks-Konczalik, J., Chu, S. C., and Moss, J. (1998) J. Biol. Chem. 273, 22201-22208[Abstract/Free Full Text]
46. Vallejo, J. G., Knuefermann, P., Mann, D. L., and Sivasubramanian, N. (2000) J. Immunol. 165, 419-425[Abstract/Free Full Text]
47. Sivasubramanian, N., and Nayak, D. P. (1987) Proc. Natl. Acad. Sci. U. S. A. 84, 1-5[Abstract/Free Full Text]
48. Baeuerle, P. A., and Baltimore, D. (1988) Cell 53, 211-217[CrossRef][Medline] [Order article via Infotrieve]
49. Dignam, J. D., Lebovitz, R. M., and Roeder, R. G. (1983) Nucleic Acids Res. 11, 1475-1489[Abstract/Free Full Text]
50. Malek, S., Huxford, T., and Ghosh, G. (1998) J. Biol. Chem. 273, 25427-25435[Abstract/Free Full Text]
51. Chen, F. E., Kempiak, S., Huang, D. B., Phelps, C., and Ghosh, G. (1999) Protein Eng. 12, 423-428[Abstract/Free Full Text]
52. Ruben, S. M., Narayanan, R., Klement, J. F., Chen, C. H., and Rosen, C. A. (1992) Mol. Cell. Biol. 12, 444-454[Abstract/Free Full Text]
53. Phelps, C. B., Sengchanthalangsy, L. L., Malek, S., and Ghosh, G. (2000) J. Biol. Chem. 275, 24392-24399[Abstract/Free Full Text]
54. Koukouritaki, S. B., Vardaki, E. A., Papakonstanti, E. A., Lianos, E., Stournaras, C., and Emmanouel, D. S. (1999) Mol. Med. 5, 382-392[Medline] [Order article via Infotrieve]
55. Yan, S. R., Fumagalli, L., Dusi, S., and Berton, G. (1995) J. Leukoc. Biol. 58, 595-606[Abstract]
56. De Vos, K., Goossens, V., Boone, E., Vercammen, D., Vancompernolle, K., Vandenabeele, P., Haegeman, G., Fiers, W., and Grooten, J. (1998) J. Biol. Chem. 273, 9673-9680[Abstract/Free Full Text]
57. Clesham, G. J., Adam, P. J., Proudfoot, D., Flynn, P. D., Efstathiou, S., and Weissberg, P. L. (1998) Gene Ther. 5, 174-180[CrossRef][Medline] [Order article via Infotrieve]
58. Borgland, S. L., Bowen, G. P., Wong, N. C., Libermann, T. A., and Muruve, D. A. (2000) J. Virol. 74, 3941-3947[Abstract/Free Full Text]
59. Morelli, A. E., Larregina, A. T., Ganster, R. W., Zahorchak, A. F., Plowey, J. M., Takayama, T., Logar, A. J., Robbins, P. D., Falo, L. D., and Thomson, A. W. (2000) J. Virol. 74, 9617-9628[Abstract/Free Full Text]
60. Holm, L., and Sander, C. (1996) Methods Enzymol. 266, 653-662[Medline] [Order article via Infotrieve]
61. Crepieux, P., Kwon, H., Leclerc, N., Spencer, W., Richard, S., Lin, R., and Hiscott, J. (1997) Mol. Cell. Biol. 17, 7375-7385[Abstract]
62. Bottero, V., Rossi, F., Samson, M., Mari, M., Hofman, P., and Peyron, J. F. (2001) J. Biol. Chem. 276, 21317-21324[Abstract/Free Full Text]
63. Lin, L., DeMartino, G. N., and Greene, W. C. (2000) EMBO J. 19, 4712-4722[CrossRef][Medline] [Order article via Infotrieve]
64. Kaltschmidt, B., and Kaltschmidt, C. (2001) Mech. Dev. 101, 11-19[CrossRef][Medline] [Order article via Infotrieve]
65. Acarin, L., Gonzalez, B., and Castellano, B. (2000) Neurosci. Lett. 288, 41-44[CrossRef][Medline] [Order article via Infotrieve]
66. Guerrini, L., Molteni, A., Wirth, T., Kistler, B., and Blasi, F. (1997) J. Neurosci. 17, 6057-6063[Abstract/Free Full Text]
67. Wong, S. C., Fukuchi, M., Melnyk, P., Rodger, I., and Giaid, A. (1998) Circulation 98, 100-103[Abstract/Free Full Text]
68. Birbach, A., Gold, P., Binder, B. R., Hofer, E., de Martin, R., and Schmid, J. A. (2002) J. Biol. Chem. 277, 10842-10851[Abstract/Free Full Text]
69. Renard, P., Percherancier, Y., Kroll, M., Thomas, D., Virelizier, J. L., Arenzana-Seisdedos, F., and Bachelerie, F. (2000) J. Biol. Chem. 275, 15193-15199[Abstract/Free Full Text]
70. Doerre, S., and Corley, R. B. (1999) J. Immunol. 163, 269-277[Abstract/Free Full Text]
71. Wilson, L., Szabo, C., and Salzman, A. L. (1999) Gastroenterology 117, 106-114[CrossRef][Medline] [Order article via Infotrieve]
72. Bergmann, M., Hart, L., Lindsay, M., Barnes, P. J., and Newton, R. (1998) J. Biol. Chem. 273, 6607-6610[Abstract/Free Full Text]
73. Ziegler-Heitbrock, L. (2001) J. Endotoxin Res. 7, 219-222[Medline] [Order article via Infotrieve]
74. Sundstedt, A., Sigvardsson, M., Leanderson, T., Hedlund, G., Kalland, T., and Dohlsten, M. (1996) Proc. Natl. Acad. Sci. U. S. A. 93, 979-984[Abstract/Free Full Text]
75. Haudek, S. B., Bryant, D. D., and Giroir, B. P. (2001) J. Mol. Cell Cardiol. 33, 1263-1271[CrossRef][Medline] [Order article via Infotrieve]
76. Adib-Conquy, M., Adrie, C., Moine, P., Asehnoune, K., Fitting, C., Pinsky, M. R., Dhainaut, J. F., and Cavaillon, J. M. (2000) Am. J. Respir. Crit. Care Med. 162, 1877-1883[Abstract/Free Full Text]
77. Hirotani, S., Otsu, K., Nishida, K., Higuchi, Y., Morita, T., Nakayama, H., Yamaguchi, O., Mano, T., Matsumura, Y., Ueno, H., Tada, M., and Hori, M. (2002) Circulation 105, 509-515[Abstract/Free Full Text]
78. Purcell, N. H., Tang, G., Yu, C., Mercurio, F., DiDonato, J. A., and Lin, A. (2001) Proc. Natl. Acad. Sci. U. S. A. 98, 6668-6673[Abstract/Free Full Text]

Copyright © 2002 by The American Society for Biochemistry and Molecular Biology, Inc.
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
B. Das, S. Gupta, A. Vasanji, Z. Xu, S. Misra, and S. Sen
Nuclear Co-translocation of Myotrophin and p65 Stimulates Myocyte Growth: REGULATION BY MYOTROPHIN HAIRPIN LOOPS
J. Biol. Chem., October 10, 2008; 283(41): 27947 - 27956.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
H. Z. Ozsoy, N. Sivasubramanian, E. D. Wieder, S. Pedersen, and D. L. Mann
Oxidative Stress Promotes Ligand-independent and Enhanced Ligand-dependent Tumor Necrosis Factor Receptor Signaling
J. Biol. Chem., August 22, 2008; 283(34): 23419 - 23428.
[Abstract] [Full Text] [PDF]

Home page
 Cardiovasc ResHome page
P. Knuefermann, M. Schwederski, M. Velten, P. Krings, H. Ehrentraut, M. Rudiger, O. Boehm, K. Fink, U. Dreiner, C. Grohe, et al.
Bacterial DNA induces myocardial inflammation and reduces cardiomyocyte contractility: role of Toll-like receptor 9
Cardiovasc Res, April 1, 2008; 78(1): 26 - 35.
[Abstract] [Full Text] [PDF]

Home page
 J. Immunol.Home page
Z. Xiong, E. Liu, Y. Yan, R. T. Silver, F. Yang, I. H. Chen, Y. Chen, S. Verstovsek, H. Wang, J. Prchal, et al.
An Unconventional Antigen Translated by a Novel Internal Ribosome Entry Site Elicits Antitumor Humoral Immune Reactions
J. Immunol., October 1, 2006; 177(7): 4907 - 4916.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
Y. Shiio, K. S. Suh, H. Lee, S. H. Yuspa, R. N. Eisenman, and R. Aebersold
Quantitative Proteomic Analysis of Myc-induced Apoptosis: A DIRECT ROLE FOR Myc INDUCTION OF THE MITOCHONDRIAL CHLORIDE ION CHANNEL, mtCLIC/CLIC4
J. Biol. Chem., February 3, 2006; 281(5): 2750 - 2756.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
R. J. O'Brien, I. Loke, J. E. Davies, I. B. Squire, and L. L. Ng
Myotrophin in human heart failure
J. Am. Coll. Cardiol., August 20, 2003; 42(4): 719 - 725.
[Abstract] [Full Text] [PDF]

Home page
 J Am Coll CardiolHome page
J. J. V. McMurray and C. Hillier
The rise and fall of myotrophin in heart failure
J. Am. Coll. Cardiol., August 20, 2003; 42(4): 726 - 727.
[Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
M. Taoka, T. Ichimura, A. Wakamiya-Tsuruta, Y. Kubota, T. Araki, T. Obinata, and T. Isobe
V-1, a Protein Expressed Transiently during Murine Cerebellar Development, Regulates Actin Polymerization via Interaction with Capping Protein
J. Biol. Chem., February 14, 2003; 278(8): 5864 - 5870.
[Abstract] [Full Text] [PDF]

Home page
 JCBHome page
S. Gupta, N. H. Purcell, A. Lin, and S. Sen
Activation of nuclear factor-{kappa}B is necessary for myotrophin-induced cardiac hypertrophy
J. Cell Biol., December 23, 2002; 159(6): 1019 - 1028.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
277/26/23888    most recent
M202937200v1
Right arrow Submit a Letter to Editor
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Knuefermann, P.
Right arrow Articles by Sivasubramanian, N.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Knuefermann, P.
Right arrow Articles by Sivasubramanian, N.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 All ASBMB Journals   Molecular and Cellular Proteomics 
 Journal of Lipid Research   ASBMB Today 
Copyright © 2002 by the American Society for Biochemistry and Molecular Biology.
Advertisement
spacer
Advertisement
Advertisement